Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Jun 29, 2026

Determining the Phagocytic Activity of Clinical Antibody Samples
09:05

Determining the Phagocytic Activity of Clinical Antibody Samples

Published on: November 30, 2011

Engineering antibodies for the clinic.

P Holliger1, H Bohlen

  • 1MRC Laboratory for Molecular Biology, Cambridge, UK. phl@mrc-lmb.cam.ac.uk

Cancer Metastasis Reviews
|June 16, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Generation and selection of hepatocyte-like cells from transgenic murine embryonic stem cells at different differentiation stages.

Journal of stem cells & regenerative medicine·2014
Same author

Intrusion of fluids into nanogrooves: how geometry determines the shape of the gas-liquid interface.

The European physical journal. E, Soft matter·2008
Same author

Inhibition of tumor growth in vivo by in situ secretion of bispecific anti-CEA x anti-CD3 diabodies from lentivirally transduced human lymphocytes.

Cancer gene therapy·2007
Same author

Implication of therapeutic cloning for organ transplantation.

European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery·2005
Same author

Identification and characterization of embryonic stem cell-derived pacemaker and atrial cardiomyocytes.

FASEB journal : official publication of the Federation of American Societies for Experimental Biology·2005
Same author

In vitro embryotoxicity assessment with dental restorative materials.

Journal of dentistry·2005
Same journal

Metastasis as a breakdown of the multicellular social contract.

Cancer metastasis reviews·2026
Same journal

HER2 assessment in urothelial carcinoma: standardization challenges and the path forward.

Cancer metastasis reviews·2026
Same journal

Resolving translational challenges in cancer biology through yeast experimental evolution.

Cancer metastasis reviews·2026
Same journal

Spheroids and organoids to study long noncoding RNAs in cancer: how they could replace animal models.

Cancer metastasis reviews·2026
Same journal

Strategies and successes of smoking cessation methods in head and neck cancer patients: a systematic review.

Cancer metastasis reviews·2026
Same journal

The Hippo signaling pathway in pediatric brain tumors: molecular mechanisms and therapeutic opportunities.

Cancer metastasis reviews·2026
See all related articles

Antibody therapeutics are emerging as a powerful new class of drugs, following the success of protein drugs. Recent advancements show promise in treating malignant lymphoma and engineering next-generation antibody treatments.

Area of Science:

  • Biotechnology
  • Immunology
  • Oncology

Background:

  • Recombinant protein drugs like erythropoietin have seen widespread clinical use over the past decade.
  • Antibody therapeutics, after initial challenges, are now gaining significant traction in clinical practice.
  • Recent approvals of chimeric and humanized antibodies by the Food and Drug Administration highlight progress in the field.

Purpose of the Study:

  • To review recent clinical applications of antibodies, with a focus on malignant lymphoma treatment.
  • To discuss current strategies for engineering whole antibodies (IgG) and antibody fragments.
  • To explore the future of antibody therapeutics.

Main Methods:

  • Review of recent clinical data and regulatory approvals for antibody drugs.

More Related Videos

Flow-pattern Guided Fabrication of High-density Barcode Antibody Microarray
09:05

Flow-pattern Guided Fabrication of High-density Barcode Antibody Microarray

Published on: January 6, 2016

Intra-iliac Artery Injection for Efficient and Selective Modeling of Microscopic Bone Metastasis
07:00

Intra-iliac Artery Injection for Efficient and Selective Modeling of Microscopic Bone Metastasis

Published on: September 26, 2016

Related Experiment Videos

Last Updated: Jun 29, 2026

Determining the Phagocytic Activity of Clinical Antibody Samples
09:05

Determining the Phagocytic Activity of Clinical Antibody Samples

Published on: November 30, 2011

Flow-pattern Guided Fabrication of High-density Barcode Antibody Microarray
09:05

Flow-pattern Guided Fabrication of High-density Barcode Antibody Microarray

Published on: January 6, 2016

Intra-iliac Artery Injection for Efficient and Selective Modeling of Microscopic Bone Metastasis
07:00

Intra-iliac Artery Injection for Efficient and Selective Modeling of Microscopic Bone Metastasis

Published on: September 26, 2016

  • Analysis of antibody engineering techniques for developing novel therapeutics.
  • Discussion of clinical trial outcomes in malignant lymphoma treated with antibodies.

    • Main Results:

    • Chimeric and humanized antibodies have received Food and Drug Administration approval in the last two years.
    • Antibodies demonstrate significant potential in the treatment of malignant lymphoma.
    • Ongoing research focuses on engineering improved antibody fragments and whole antibodies for enhanced efficacy.

    Conclusions:

    • Antibody therapeutics are a rapidly advancing area with significant clinical potential.
    • Engineering efforts are paving the way for next-generation antibody treatments.
    • Further development is expected to broaden the application of antibody-based therapies in oncology and beyond.